The GLP-1 Agonist Debate: How Safe Are Victoza and Bydureon?

The GLP-1 Agonist Debate: How Safe Are Victoza and Bydureon?

The Agonist Debate: How Safe Are Victoza and Bydureon?

Effect of gravity on volume of placental transfusion: a multicentre, randomised, non-inferiority trial : The Lancet

Neurobehavioural effects of developmental toxicity

What are GLP-1 Agonists and why are these drugs important to CPT’s research? Liraglutide, Lixisenatide and Exenatide (the synthetic form of Exendin-4) belong to a group of safe and well tolerated drugs called Glucagon-like peptide (GLP-1) agonists designed to mimic the action of human gut hormones or incretins (see Christian Holscher's pre-clinical work). The glucagon-like peptide-1 (GLP-1) receptor agonists increase the incretin effect in patients with type 2 diabetes, stimulat...

Decades into diabetes, insulin therapy still hard to manage -

Insulin/GLP-1 Agonist Combinations: Time for Early and Effective Intervention

Agonist Combinations: Time for Early and Effective Intervention

The GLP-1 Agonist Debate: How Safe Are Victoza and Bydureon?

The GLP-1 Agonist Debate: How Safe Are Victoza and Bydureon?

The Agonist Debate: How Safe Are Victoza and Bydureon?

The GLP-1 Agonist Debate: How Safe Are Victoza and Bydureon?

The GLP-1 Agonist Debate: How Safe Are Victoza and Bydureon?

Don't let GRE Test Day myths keep you from focusing on the most important thing—your GRE score. Get a sense of where you stand with our Score Predictor Quiz.

Liraglutide (NN2211), marketed under the brand name Victoza, is a long-acting glucagon-like peptide-1 agonist (GLP-1 agonist)

Liraglutide marketed under the brand name Victoza, is a long-acting glucagon-like agonist agonist)

A meta-analysis suggests overall benefit of GLP-1 agonists in patients with type 2 diabetes at moderate to high cardiovascular risk, but individual agents differ in clinically relevant parameters.

A meta-analysis suggests overall benefit of agonists in patients with type 2 diabetes at moderate to high cardiovascular risk, but individual agents differ in clinically relevant parameters.

GLP - 1 agonist in treatment of diabetes.

GLP - 1 agonist in treatment of diabetes.

Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease - ScienceDirect

Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease - ScienceDirect

Clinical Advances in Diabetes Management with GLP-1 Agonists

Clinical Advances in Diabetes Management with Agonists

Exenatide (Byetta) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication approved in April 2005 for the treatment of diabetes mellitus type 2. It belongs to the group of incretin mimetics. 1 Increases insulin secretion 2 suppresses pancreatic release of glucagon in response to eating 3 slow down gastric emptying 4 reduce appetite 5 Exenatide reduces liver fat content.

Exenatide (Byetta) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication approved in April 2005 for the treatment of diabetes mellitus type 2. It belongs to the group of incretin mimetics. 1 Increases insulin secretion 2 suppresses pancreatic release of glucagon in response to eating 3 slow down gastric emptying 4 reduce appetite 5 Exenatide reduces liver fat content.

A review of how far GLP-1 agonists have come – drugs for type 2 diabetes that help with not only blood sugar management, but with weight loss and heart health too

A review of how far GLP-1 agonists have come – drugs for type 2 diabetes that help with not only blood sugar management, but with weight loss and heart health too

Cure Parkinson's Trust | GLP-1 Agonists – the facts

close up of insulin syringes on table

Pinterest
Search